GSW Worldwide for MGI Pharma/Eisai's PONV
Pharmaceutical Executive
To educate anesthesiologists that post-operative nausea and vomiting (PONV) is "no fun for anyone," GSW Worldwide created WoozyWorld.com, a "non-amusement" that highlights the need for MGI Pharma's 72-hour antiemetic Aloxi.
WOOZYWORLD
GSW Worldwide
BRAND Market education for PONV CLIENT MGI Pharma/Eisai FROM LEFT: (Seated): Sean Cowan, creative director, digital wave; Kristan Early, vice president, creative director; (Standing): Dean Tepper, senior vice president, group creative director; Seth Quillin, senior vice president, digital operations
To educate anesthesiologists that post-operative nausea and vomiting (PONV) is "no fun for anyone," GSW Worldwide created WoozyWorld.com, a "non-amusement" that highlights the need for MGI Pharma's 72-hour antiemetic Aloxi. The team unveiled the unmistakable (yet unbranded) site before the drug's March 2008 launch. "Creatively, we gave WoozyWorld a darker, tongue-in-cheek edge," says Sean Cowan, creative director, digital wave. They drew inspiration from the retail industry—which is more forward-looking than the pharmaceutical space—to create great, engaging content.
WoozyWorld includes information on the very real consequences of patients' post-operative side effects—with the goal to "make [anesthesiologists] care a little bit longer." "When patients undergo anesthesia, all anesthesiologists really care about is the first 24 hours after surgery," says Kristan Early, vice president, creative director. "Once patients are discharged, anesthesiologists feel their job is done. But in reality, a patient can still become sick once they arrive home or even days later."
FDA Outlines Updated Requirement for Placebo-Controlled Trials in Vaccine Research
May 21st 2025In an article recently published by The New England Journal of Medicine, FDA higher-ups Vinay Prasad, MD, MPH; and Martin A. Makary, MD, MPH, wrote that any new COVID-19 vaccine must now be evaluated in placebo-controlled studies.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
